Therapeutic potency of IL2–caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease

• Published in: Gut Vol. 58; no. 6; pp. 790 - 798
• Main Authors: Shteingart, S, Rapoport, M, Grodzovski, I, Sabag, O, Lichtenstein, M, Eavri, R, Lorberboum-Galski, H
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.06.2009; BMJ Publishing Group; BMJ Publishing Group LTD
• Subjects: Acute Disease; Animals; Apoptosis; Autoimmune diseases; Biological and medical sciences; Caspase 3 - genetics; Caspase 3 - metabolism; Colitis - drug therapy; Colitis - enzymology; Colitis - immunology; Colon - drug effects; Colon - immunology; Crohns disease; Dextran Sulfate; Dose-Response Relationship, Drug; Gastroenterology. Liver. Pancreas. Abdomen; Gene Expression - drug effects; Genes, bcl-2; Genetic Engineering; Immune system; Inflammation; Inflammatory bowel disease; Interleukin-2 - genetics; Interleukin-2 - metabolism; Lymphocyte Activation; Lymphocytes; Male; Medical sciences; Mice; Mice, Inbred BALB C; Models, Animal; Neutrophils - immunology; Other diseases. Semiology; Proteins; Recombinant Fusion Proteins - therapeutic use; RNA, Messenger - analysis; Rodents; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; T-Lymphocytes - immunology; Enzyme; Rodentia; Caspase; Inflammatory disease; Peptidases; Crohn disease; Vertebrata; Mammalia; Treatment; Mouse; Animal; Gastroenterology; Hydrolases; Digestive diseases; Intestinal disease; Models; Ulcerative colitis

Background:Inflammatory bowel disease (IBD) comprises primarily the two disorders – ulcerative colitis and Crohn’s disease – that involve deregulated T cell responses. The ever-increasing incidence rate of Crohn’s disease and ulcerative colitis during recent decades, combined with the limited effica...